360 MD - Medical Weight Loss

360 MD - Medical Weight Loss in Buda, Texas, operates under the clinical direction of Dr. Carol Ann Linebarger, a board-certified physician with specialized training through the American Academy of Anti-Aging Medicine. The clinic focuses on physician-supervised weight management programs that integrate GLP-1 receptor agonist medications with functional medicine principles, addressing metabolic health from multiple angles rather than relying solely on pharmacotherapy. Dr. Linebarger's anti-aging medicine certification informs her approach to weight loss as a component of broader metabolic optimization, examining how body composition changes affect hormonal balance, cardiovascular risk markers, and long-term health outcomes in patients across Central Texas.

The clinic's weight loss protocols center on two FDA-approved GLP-1 medications: semaglutide and tirzepatide. Semaglutide functions as a glucagon-like peptide-1 receptor agonist that enhances insulin secretion, suppresses glucagon release, and slows gastric emptying to reduce appetite and caloric intake. Tirzepatide represents a dual GIP/GLP-1 receptor agonist mechanism, activating both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 pathways for enhanced glycemic control and weight reduction. 360 MD structures these medications within comprehensive programs that include baseline metabolic assessments, dosage titration schedules based on individual tolerance and response, and ongoing monitoring of body composition changes rather than scale weight alone. The clinic's functional health orientation means providers evaluate thyroid function, cortisol patterns, sex hormone levels, and nutrient status as factors that influence medication efficacy and sustainable weight management outcomes.

Dr. Linebarger's clinical model emphasizes the distinction between weight loss and metabolic health improvement, recognizing that optimal outcomes require addressing insulin resistance, inflammatory markers, and hormonal imbalances that often underlie weight gain. Her American Academy of Anti-Aging Medicine training provides frameworks for assessing biological age markers and age-related metabolic decline, which informs treatment strategies for patients experiencing weight gain associated with perimenopause, andropause, or metabolic syndrome. The Buda location serves patients throughout Hays County and the Austin metropolitan area, offering both in-person consultations at the clinic and telehealth appointments for established patients across Texas who require ongoing medication management and program adjustments without travel to the physical office.

Patients beginning treatment at 360 MD undergo initial consultations that include medical history review, current medication assessment, weight loss goal discussion, and evaluation for contraindications to GLP-1 therapy such as personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. The clinic provides structured onboarding for patients new to these medications, including education on injection technique for subcutaneous administration, recognition of common side effects like nausea or gastrointestinal changes during dose escalation, and strategies for optimizing protein intake and resistance training to preserve lean muscle mass during caloric deficit periods. Follow-up schedules typically involve monthly check-ins during the first quarter of treatment, with intervals adjusted based on individual progress and any dose modifications required for tolerability or efficacy optimization.

The hybrid care model at 360 MD accommodates the realities of patient schedules in the rapidly growing Buda area, where many residents commute to Austin or San Antonio for work. Texas residents can access telehealth consultations for medication refills, side effect management, and program adjustments once the initial in-person assessment establishes the patient-provider relationship and treatment safety. This flexibility supports adherence for patients managing demanding work schedules while maintaining the clinical oversight necessary for safe GLP-1 medication use. The clinic's focus on habit modification and sustainable lifestyle changes, reflected in patient feedback about goal-setting and health habit development, distinguishes the program from prescription-only approaches by addressing the behavioral and metabolic factors that will determine long-term weight maintenance after medication discontinuation or dose reduction.